As we await mature results from ongoing studies, it is crucial to consider emergent observations that could impact the efficacy of CD123-targeted immunotherapies to enhance antineoplastic responses and elevate the survival rates for patients dealing with BPDCN and related CD123 neoplasms. The gene discussed is IL3RA; the disease is CD4+/CD56+ hematodermic neoplasm.